The Efficacy of Non–Vitamin K Antagonist Oral Anticoagulants in the Prevention of Left Atrial Thrombus in Patients With Atrial Fibrillation Compared With Vitamin K Antagonists: A Meta-Analysis

Jun Liu, MD, Yi-Ping Wu, MD, Shu-Rui Li, MD, Li-Hong Song, MD, Cheng-Dong Hu, MD

1Department of Geratology, Handan Central Hospital, Hebei, Handan, China; 2Department of Neurology, Handan Central Hospital, Hebei, Handan, China; 3Imaging Department, Handan Central Hospital, Hebei, Handan, China; 4Department of Orthopedics, Handan Central Hospital, Hebei, Handan China

ABSTRACT

Background: There is still a paucity of data on the efficacy of non–vitamin K antagonist oral anticoagulants (NOACs) in the prevention of left atrial thrombus (LAT) formation before cardioversion or catheter ablation. To assess the efficacy of NOACs in the prevention of LAT in patients with non-valvular atrial fibrillation (NVAF) compared with vitamin K antagonists (VKAs), we conducted a meta-analysis.

Methods: We searched PubMed, Embase, and the Cochrane Library databases. For meta-analysis, dichotomous variables were analyzed by using the odds ratios (OR) computed using the Mantel Haenszel method (random models). All results were reported with 95% confidence intervals (CI).

Results: A total of 13 studies (one randomized controlled investigation and 12 observational studies) were included in the meta-analysis. There was no statistically significant difference between the NOACs and VKAs groups with respect to the odds of LAT/LAAT formations (OR 0.79; 95% CI: 0.52-1.21; \( P = .29; \ (I^2 = 14\%\)).

Conclusions: NOACs were as effective as VKAs in the prevention of LAT/LAAT formation in patients with NVAF. Though patients on NOACs therapy showed a lower incidence of LAT/LAAT formation compared with VKAs, it was not significant (\( P = .29\)).

INTRODUCTION

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias. Hypertension, aging, and congestive heart failure are all strong clinical predictors of AF [Schotten 2011]. Atrial contractile dysfunction in AF patients contributes to the formation of left atrial thrombus. One study suggests that LAT is present in 10% of patients with AF, causing a 3.5-fold increased risk of stroke and systemic embolism [Di Minno 2016].

Anticoagulation therapy is an effective measure to prevent thromboembolism in patients with AF. According to guidelines,

Received July 19, 2020; accepted August 17, 2020.

Correspondence: Yi-Ping Wu, director, Department of Neurology, Handan Central Hospital, Hebei, Handan, China 056001 (e-mail: Wuyphd@163.com).
patients should be treated with either NOAC or VKA for at least three weeks before cardioversion [January 2019]. VKAs are traditional anticoagulant agents, among which, warfarin is the most widely used. However, it should be noted that warfarin is known to interact with food and many drugs, increasing the risk of adverse events. Inadequate monitoring of the international normalized ratio (INR) may lead to major bleeding and thrombosis recurrence. Furthermore, despite full anticoagulation on warfarin, 3.6% of patients undergoing AF ablation had left atrial appendage (LAA) thrombus [Wallace 2010]. Non–vitamin K antagonist oral anticoagulants (NOACs) include a direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban). NOACs are more convenient than warfarin. They are promising alternatives to warfarin for prevention of stroke in non-valvular atrial fibrillation (NVAF) patients. However, there’s little data about left atrial thrombus detected in AF patients treated with NOACs. Research shows that the incidence of LAA thrombus in patients treated with NOACs is not negligible [Bertaglia 2017]. There is still controversy regarding the efficacy of NOACs for LAT prevention in NVAF compared with VKAs. Some studies indicate that the incidence of left atrial thrombus was lower in patients treated with NOAC than patients treated with warfarin [Yang 2019; Schaeffer 2018], while others do not [Reers 2016; Kawabata 2017]. Furthermore, the clinical trials of NOACs inconsistently reported race/ethnicity [Jackson 2018]. Therefore, we aimed to explore the efficacy of NOACs for LAT prevention in NVAF compared with VKAs.

**METHODS**

This meta-analysis was performed in accordance with Cochrane’s Handbook guidelines [Higgins 2011], and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [Moher 2009].

**Literature search:** To identify eligible studies, we searched PubMed, Embase, and the Cochrane Library databases. MeSH terms included “atrial fibrillation,” “anticoagulants,” and “transesophageal echocardiography.” The final literature search was performed on October 1, 2019.

**Study selection inclusion and exclusion criteria:** The inclusion criteria for our studies were as follows: (1) human studies; (2) patients with NVAF who were treated with NOACs, and (3) studies that reported data on left atrial thrombus.

**Table 1. Baseline characteristics of the selected studies**

<table>
<thead>
<tr>
<th>Study, Year (Reference)</th>
<th>Study Design</th>
<th>NOACs</th>
<th>Sample size, n</th>
<th>Number of LA/LAA thrombus</th>
<th>Mean age, years</th>
<th>Male sex, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NOAC</td>
<td>VKA</td>
<td>NOAC</td>
</tr>
<tr>
<td>Kim YG, et al. 2018</td>
<td>Retrospectively analyzed</td>
<td>Dabigatran, Rivaroxaban, Apixaban, and Edoxaban</td>
<td>164</td>
<td>180</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Schaeffer B, et al. 2018</td>
<td>Prospective investigation</td>
<td>Rivaroxaban, Dabigatran and Apixaban</td>
<td>526</td>
<td>396</td>
<td>13</td>
<td>21</td>
</tr>
<tr>
<td>Tint D, et al. 2017</td>
<td>Prospective study</td>
<td>NR</td>
<td>58</td>
<td>45</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Wyrembak J, et al. 2017</td>
<td>Retrospective study</td>
<td>Dabigatran</td>
<td>420</td>
<td>517</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Barysiene J, et al. 2017</td>
<td>Retrospective study</td>
<td>Dabigatran, Rivaroxaban, and Apixaban</td>
<td>49</td>
<td>71</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Kawabata M, et al. 2017</td>
<td>Retrospective study</td>
<td>Dabigatran, Rivaroxaban, Apixaban, and Edoxaban</td>
<td>311</td>
<td>248</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Gunawardene MA, et al. 2017</td>
<td>Retrospective registry</td>
<td>Dabigatran, Rivaroxaban, Apixaban, or Edoxaban</td>
<td>1035</td>
<td>380</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>Reers S, et al. 2016</td>
<td>Retrospective study</td>
<td>Dabigatran, Rivaroxaban</td>
<td>168</td>
<td>138</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Frenkel D, et al. 2016</td>
<td>Retrospective study</td>
<td>Dabigatran, Rivaroxaban, Apixaban</td>
<td>183</td>
<td>205</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Somani R, et al. 2014</td>
<td>Retrospective study</td>
<td>Dabigatran</td>
<td>39</td>
<td>86</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Kim JS, et al. 2013</td>
<td>Case-control analysis</td>
<td>Dabigatran</td>
<td>191</td>
<td>572</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Maddox W, et al. 2013</td>
<td>Retrospective study</td>
<td>Dabigatran</td>
<td>212</td>
<td>251</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Nagarakanti R, et al. 2011</td>
<td>RCT</td>
<td>Dabigatran</td>
<td>327</td>
<td>88</td>
<td>5</td>
<td>1</td>
</tr>
</tbody>
</table>
or VKAs; (3) TEE was used to detect the LAT/LAAT before the cardioversion or catheter ablation; (4) studies comparing NOACs with VKAs in patients with LAT; and (5) randomized controlled and observational study design. The exclusion criteria were the following: (1) studies without VKAs or NOACs as comparator; (2) review, case reports, and letters were excluded; and (3) LAA Occlusion/Excision.

Data extraction and quality assessment: Relevant information from included studies, according to the predefined inclusion criteria, was extracted. Two reviewers independently assessed the quality of included studies, according to the Cochrane Handbook and all disagreements between them were resolved through discussion. We assessed the risk of bias using the Cochrane Risk of Bias tool, which addresses six specific domains: sequence generation, allocation concealment, blinding, incomplete outcome data, no selective outcome reporting, and other sources of bias.

Statistical analysis: For meta-analysis, dichotomous variables were analyzed by using the odds ratios (OR) computed using the Mantel Haenszel method (random models). All results were reported with 95% confidence intervals (CI). I-square (I²) test was used to assess the impact of heterogeneity on the results of the meta-analysis, with F values of 0%, 25%, 50% and 75%, respectively, representing no, low, moderate, and high heterogeneity. All analyses were carried out using Review Manager (RevMan) Version 5.3.
RESULTS

Included studies: We initially searched 817 records. After removal of duplicates, 693 records were screened. We excluded 594 records after reading the title and abstract. Of the 99 records, 86 records were excluded after the full-text articles were assessed. Thirteen records were assessed for eligibility. Finally, 13 articles that fulfilled the inclusion criteria were identified. The flowchart of the search and selection is illustrated in Figure 1.

Study characteristics and quality evaluation: Overall, 6,860 patients from 13 studies were included in the analysis, of which 3,683 patients were treated with NOACs and 3,177 patients were treated with VKAs [Schaeffer 2018; Reers 2016; Kawabata 2017; Wyrembak 2017; Kim 2013; Maddox 2013; Nagarakanthi 2011; Barysiene 2017; Kim 2018; Tînţă 2017; Frenkel 2016; Gunawardene 2017; Somani 2014]. All patients were examined by TEE prior to cardioversion or catheter ablation. The mean age of the patients ranged from 59.9 ± 11.5 to 66.4 ± 9.79 years.

The proportion of males ranged from 20 to 83.7. Baseline characteristics of the selected studies are illustrated in Table 1. Among the studies, two studies included the subjects’ race characteristics, indicating that there were no significant race differences between warfarin group and the dabigatran group (P > .05) (Table 2). Studies with an I² statistic of <25% was considered to have no heterogeneity. The funnel plot did not indicate a high risk of publication bias (Figure 4).

Meta-analysis: There was no statistically significant difference between the NOACs and VKAs groups with respect to the odds of LAT/LAAT formations (OR 0.79; 95% CI: 0.52-1.21; P = .29; (I² = 14%). Figure 3 shows forest plots presenting included studies. A total of 128 LAT events were reported in the entire study population (62 in NOACs versus 66 in VKAs patients).

Among the 13 reports included in the meta-analysis, there were randomized controlled investigations or observational studies. Of these, one was a controlled investigation, and 12 were observational studies. In observational studies, the comparison between NOACs and VKAs revealed no significant difference (OR = 0.78; 95% CI: 0.50 – 1.23) (Figure 2).
NOACs were as effective as VKAs in the prevention of LAT/LAAT formation in patients with NVAF. Though patients on NOACs therapy showed a lower incidence of LAT/LAAT formation compared with VKAs, it was not significant ($P = .29$). The 95% CI covered the one.

**DISCUSSION**

The goal of this meta-analysis is to assess the efficacy of NOACs for LAT prevention in non-valvular atrial fibrillation compared with VKAs. The results of our meta-analysis are as follows: The incidence of LAT/LAAT formation in patients undergoing TEE prior to CV or catheter ablation appeared to be similar in patients with NOACs therapy compared with VKAs therapy (OR 0.79, 95% CI: 0.52 - 1.21, $P = .29$).

Rhythm control is an important strategy for patients with AF, including cardioversion, antiarrhythmic drugs, and radio-frequency catheter [January 2014]. According to guidelines for patients with AF of 48 hours’ duration or longer, anticoagulation with warfarin, NOACs (a factor Xa inhibitor or direct thrombin inhibitor) is recommended for at least three weeks before cardioversion [January 2019]. Catheter ablation also is a reasonable rhythm-control strategy for patients with AF. It should be noted that, in the setting of appropriate anticoagulation, the incidence of thrombus formation in AF patients undergoing TEE prior to catheter ablation or cardioversion should not be ignored. LAT is reported in patients receiving anticoagulation and the screening of LAT in patients with AF before cardioversion or ablation should be made [Di Minno 2016].

TEE currently is considered the gold standard modality for detecting LAT/LAAT, with high sensitivity and high specificity of 95%–100% [Patti 2017; Hahn 2013; Manning 1995], which can be performed before cardioversion to identify the LAT/LAAT [Klein 2001]. However, there still is little solid evidence on the efficacy of NOACs in LAT/LAAT resolution. We conducted meta-analysis to assess the efficacy of NOACs for LAT/LAAT prevention in non-valvular atrial fibrillation compared with VKAs. There are different opinions among the efficacy of prevention of left atrial thrombus between NOACs and VKAs [Yang 2019; Reers 2016]. We reviewed the published meta-analyses. One study indicated similar incidence of thrombus formation in patients with AF between NOACs and VKAs [Reers 2018]. This research included four trials: ARISTOTLE, ENSURE-AF, RE-LY Dabigatran, and X-VeRT. Of these trials, ENSURE-AF and X-VeRT are prospective randomized clinical trials for electrical cardioversion in AF patients. The results of ENSURE-AF were independent of the TEE-guided strategy [Goette 2016]. Some studies also included the AF patients undergoing cardioversion [Téllez-Garcia 2018]. Another study revealed the LAT resolution rate was 63.7% [Wang 2018]. One study indicated that among initiators of oral anticoagulation, direct-acting oral anticoagulants use was low [Essien 2020]. In this meta-analysis, we included studies that evaluated the efficacy of LAT/LAAT prevention between NOACs and VKAs in patients undergoing cardioversion [Schaeffer 2018; Barysié 2017; Kim 2018; Ţînt 2017], or catheter ablation [Frenkel 2016; Gunawardene 2017; Somani 2014], or both [Reers 2016]. Additionally, some studies focus on the AF patients undergoing cardiac surgery, elective cardioversion, or catheter ablation.

GDF-15 is associated with AF-related complications [Zhou 2019]. This meta-analysis provided insights into the effects of the anticoagulation on incidence of thrombus in AF patients.

In one study, comparing with White, African-American race is one of predictors of persistence on warfarin [Jackson 2018]. Another previous trial reviewed data from 30 trials of NOACs, revealing that 21 trials reported race/ethnicity data [Jackson 2015]. It was notable that approximately 2% were Black in enrollment by race [Jackson 2015]. The relative efficacy of NOACs in minority populations is unknown [Jackson 2015]. In the present analysis, we tried to provide a review of the two studies, including the subjects’ race characteristics. We found that there were no significant race differences between the warfarin group and dabigatran group at baseline.

Our study has some limitations. Most of the studies included had small sample sizes. The studies also had different protocols. Furthermore, most data came from observational studies. The analysis of the pooled data showed a similar effect of NOACs, in terms of incidence of LAT/LAAT formations compared with the VKAs. Though patients on NOACs therapy showed a lower incidence of thrombus compared with VKAs, it was not significant. Whether the potential benefit could be proved in future, well-designed studies is not known. Moreover, whether the LAT/LAAT have been in existence prior to anticoagulant therapy is not clear because the TEE was not necessary before the initial anticoagulant therapy.

<table>
<thead>
<tr>
<th>Study, Year (Reference)</th>
<th>Race</th>
<th>Dabigatran</th>
<th>Warfarin</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim JS, et al 2013</td>
<td></td>
<td>191</td>
<td>572</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Race: Caucasian</td>
<td>184 (96%)</td>
<td>553 (97%)</td>
<td>.82</td>
</tr>
<tr>
<td>Maddox W, et al 2013</td>
<td></td>
<td>212</td>
<td>251</td>
<td></td>
</tr>
<tr>
<td></td>
<td>White race</td>
<td>195 (92%)</td>
<td>233 (93%)</td>
<td>.87</td>
</tr>
<tr>
<td></td>
<td>Non-white race</td>
<td>17 (8%)</td>
<td>18 (7%)</td>
<td>.73</td>
</tr>
</tbody>
</table>
CONCLUSION

Taken together, these results suggest the incidence of thrombus was similar for AF patients on NOACs and VKAs.

REFERENCES


Circulation. 130(23):e199-e267.


